IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in non-diabetic but not diabetic subjects

BMC Immunology

Said Dermime³  Mohammed Dehbi⁴  Kazem Behbehani⁵  Monira Al-Arouj⁵  Abdullah Bennakhi⁵  Rasheed Ahmad²  Asma Al-Hubail¹  Samia Warsame⁴  Fahad Al-Ghimlas⁶  Amal Hasan² 

[1] Clinical Laboratory, Dasman Diabetes Institute, Kuwait City, Kuwait;Immunology and Innovative Cell Therapy Unit, Dasman Diabetes Institute, Kuwait City, Kuwait;Biomedical Research Facility, King Khalid Medical City Center for Health Research, King Fahad Specialist Hospital Dammam, MBC-074, Bldg 100, Office 31, PO Box 15215, Dammam 31444, Kingdom of Saudi Arabia;Biochemistry and Molecular Biology Unit, Dasman Diabetes Institute, Kuwait City, Kuwait;Senior Management, Dasman Diabetes Institute, Kuwait City, Kuwait;Fitness and Rehabilitation Centre, Dasman Diabetes Institute, Kuwait City, Kuwait

关键词: BMI;    TGL;    LDL-C;    HDL-C;    Atherosclerosis;    Interleukin-33;   

Others  :  848369
DOI  :  10.1186/1471-2172-15-19

 received in 2013-10-09, accepted in 2014-04-28,  发布年份 2014

【 摘 要 】

Objective

Recent studies have demonstrated a protective role for IL-33 against obesity-associated inflammation, atherosclerosis and metabolic abnormalities. IL-33 promotes the production of T helper type 2 (Th2) cytokines, polarizes macrophages towards a protective alternatively activated phenotype, reduces lipid storage and decreases the expression of genes associated with lipid metabolism and adipogenesis. Our objective was to determine the level of serum IL-33 in non-diabetic and diabetic subjects, and to correlate these levels with clinical (BMI and body weight) and metabolic (serum lipids and HbA1c) parameters.

Methods

The level of IL-33 was measured in the serum of lean, overweight and obese non-diabetic and diabetic subjects, and then correlated with clinical and metabolic parameters.

Results

Non-lean subjects had significantly (P = 0.01) lower levels of IL-33 compared to lean controls. IL-33 was negatively correlated with the BMI and body weight in lean and overweight, but not obese (non-diabetic and diabetic), subjects. IL-33 is associated with protective lipid profiles, and is negatively correlated with HbA1c, in non-diabetic (lean, overweight and obese) but not diabetic subjects.

Conclusions

Our data support previous findings showing a protective role for IL-33 against adiposity and atherosclerosis, and further suggest that reduced levels of IL-33 may put certain individuals at increased risk of developing atherosclerosis and insulin resistance. Therefore, IL-33 may serve as a novel marker to predict those who may be at increased risk of developing atherosclerosis.

【 授权许可】

   
2014 Hasan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 1.

【 参考文献 】

• [1]Kahn SE, Hull RL, Utzschneider KM: Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444(7121):840-846.
• [2]O'Hare AM, Tawney K, Bacchetti P, Johansen KL: Decreased survival among sedentary patients undergoing dialysis: results from the dialysis morbidity and mortality study wave 2. Am J Kidney Dis 2003, 41(2):447-454.
• [3]Knoeche B, Lohr J, Kahn E, Bluestone JA, Abbas AK: Sequential development of interleukin 2–dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med 2005, 202:1375-1386.
• [4]Vykoukal D, Davies MG: Vascular biology of metabolic syndrome. J Vasc Surg 2011, 54(3):819-831.
• [5]Donath MY, Shoelson SE: Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011, 11(2):98-107.
• [6]Murphy NF, MacIntyre K, Stewart S, Hart CL, Hole D, McMurray JJ: Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study). Eur Heart J 2006, 27(1):96-106.
• [7]Rocha VZ, Libby P: Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009, 6(6):399-409.
• [8]Gregor MF, Hotamisligil GS: Inflammatory mechanisms in obesity. Annu Rev Immunol 2011, 29:415-445.
• [9]Lago F, Dieguez C, Gomez-Reino J, Gualillo O: Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007, 3(12):716-724.
• [10]Zeyda M, Stulnig TM: Obesity, inflammation, and insulin resistance–a mini-review. Gerontology 2009, 55(4):379-386.
• [11]McLaren JE, Michael DR, Salter RC, Ashlin TG, Calder CJ, Miller AM, Liew FY, Ramji DP: IL-33 reduces macrophage foam cell formation. J Immunol 2010, 185(2):1222-1229.
• [12]Lusis AJ: Atherosclerosis. Nature 2000, 407(6801):233-241.
• [13]Andersson J, Libby P, Hansson GK: Adaptive immunity and atherosclerosis. Clin Immunol 2010, 134(1):33-46.
• [14]Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352(16):1685-1695.
• [15]Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA: IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23(5):479-490.
• [16]Miller AM, Liew FY: The IL-33/ST2 pathway–A new therapeutic target in cardiovascular disease. Pharmacol Ther 2011, 131(2):179-186.
• [17]Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP: IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 2007, 104(1):282-287.
• [18]Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, Xu D, Sattar N, McInnes IB, Liew FY: Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res 2010, 107(5):650-658.
• [19]Sakashita M, Yoshimoto T, Hirota T, Harada M, Okubo K, Osawa Y, Fujieda S, Nakamura Y, Yasuda K, Nakanishi K, Tamari M: Association of serum interleukin-33 level and the interleukin-33 genetic variant with Japanese cedar pollinosis. Clin Exp Allergy 2008, 38(12):1875-1881.
• [20]Liew FY, Pitman NI, McInnes IB: Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010, 10(2):103-110.
• [21]Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, Baker AH, McInnes IB, Liew FY: IL-33 reduces the development of atherosclerosis. J Exp Med 2008, 205(2):339-346.
• [22]Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT: IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007, 117(6):1538-1549.
• [23]Turnquist HR, Zhao Z, Rosborough BR, Liu Q, Castellaneta A, Isse K, Wang Z, Lang M, Stolz DB, Zheng XX, Demetris AJ, Liew FY, Wood KJ, Thomson AW: IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 2011, 187(9):4598-4610.
• [24]Pawlak K, Mysliwiec M, Pawlak D: Oxidized LDL to autoantibodies against oxLDL ratio - The new biomarker associated with carotid atherosclerosis and cardiovascular complications in dialyzed patients. Atherosclerosis 2012, 224(1):252-257.
• [25]Zeyda M, Wernly B, Demyanets S, Kaun C, Hammerle M, Hantusch B, Schranz M, Neuhofer A, Itariu BK, Keck M, Prager G, Wojta J, Stulnig TM: Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes (Lond) 2013, 37(5):658-665.
• [26]Miller AM, Purves D, McConnachie A, Asquith DL, Batty GD, Burns H, Cavanagh J, Ford I, McLean JS, Packard CJ, Shiels PG, Turner H, Velupillai YN, Deans KA, Welsh P, McInnes IB, Sattar N: Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PLoS One 2012, 7(10):e47830.
• [27]Hoerger TJ, Segel JE, Gregg EW, Saaddine JB: Is glycemic control improving in U.S. adults? Diabetes Care 2008, 31(1):81-86.
• [28]Kwon H, Pessin JE: Adipokines mediate inflammation and insulin resistance. Front Endocrinol (Lausanne) 2013, 4:71.